The group’s CD47 x CD20 fusion protein will soon go into a Chinese phase 3.
ApexOnco Front Page
Recent articles
Tecvayli and Hernexeos might get speedy approval decisions.
So who else could be interested in the oestrogen degrader?
A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
After menin, the company tries again with farnesyl transferase.
The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.
The Rainfol-03 trial, in second-line endometrial cancer, builds on recent early data.
The companies clash over survival curve similarities – and differences.
